行情

XERS

XERS

Xeris Pharmaceuticals
NASDAQ

实时行情|Nasdaq Last Sale

8.75
+0.07
+0.81%
盘后: 8.75 0 0.00% 16:53 12/06 EST
开盘
8.63
昨收
8.68
最高
8.85
最低
8.37
成交量
14.35万
成交额
--
52周最高
20.90
52周最低
6.85
市值
1.67亿
市盈率(TTM)
-1.9255
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

XERS 新闻

  • 法国兴业银行:美债收益率或将因衰退风险而跌至1.2%
  • 环球外汇网官网.4天前
  • OPEC+分歧仍严重 或仅能延长现有减产规模
  • 新浪财经综合.4天前
  • 意大利内阁举行会议 预计将会批准意航4亿欧元贷款
  • 中国新闻网.4天前
  • 报告称今年全球贸易增速或创近10年新低
  • 新浪财经综合.4天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

XERS 简况

Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing injectable and infusible drug formulations. It uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. Its formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of formulations of peptides, proteins, antibodies and small molecules using commercially-available syringes, auto-injectors, multi-dose pens and infusion pumps. The Company is developing its lead product candidate, the Glucagon Rescue Pen, for the treatment of severe hypoglycemia in people with diabetes. It is also developing treatments for post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen offers a stable glucagon that is designed to be administered subcutaneously in a simple two-step process.
展开

Webull提供Xeris Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。